Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of VX-581 Tablet vs Suspension in Healthy Adults
NCT07813039Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Sep 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VX-581 in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration Versus Time Curve. Started Sep 2026; status: active, not recruiting.
02
Drugs
VX-581
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07813039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07813039.